A Phase I/IIa Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Study Details
Study Description
Brief Summary
This is a Phase I Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of IAP0971 in Patients with Advanced Malignant Tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1/Phase 2 |
Detailed Description
The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa).First, the Phase Ia dose escalation will be carried out. After finishing the Phase 1a，the Phase Ib dose extension study can be carried out in the MTD dose which can be achieved from Phase 1a. After Phase Ia & Ib are completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Phase Ia - Dose escalation The goal of the Dose Escalation Phase (Part A) is to initially characterize the safety and tolerability of IAP0971, and more specifically to describe the DLTs for each dose level studied and to define the MTD based on the frequency of the occurrence of DLTs in each cohort during the DLT evaluation period. |
Drug: IAP0971
IAP0971 should be subcutaneous injected，q2w
|
| Experimental: Phase Ib - Dose extension During the Dose Expansion Phase , patients will be enrolled to receive IAP0971 at the MTD established from the Dose Escalation Phase of the study. |
Drug: IAP0971
IAP0971 should be subcutaneous injected，q2w
|
| Experimental: Phase IIa - Clinical Exploratory Stage After finishing Phase 1, invesigators will discuss with the sponsor about how to carry out the Phase IIa due to the results acheived from Phase I. |
Drug: IAP0971
IAP0971 should be subcutaneous injected，q2w
|
Outcome Measures
Primary Outcome Measures
- To evaluate the safety of IAP0971 (Phase I) [Through finishing Phase I, an average of 1 year]
MTD/RP2D; Incidence and frequency of DLT; AE, SAE occurrence and frequency (according to NCI CTCAE 5.0).
- To evaluate the effectiveness of IAP0971 (Phase IIa) [Until disease progression, assessed up to 3 years]
Objective response rate(ORR)
Secondary Outcome Measures
- Pharmacokinetics (PK) Cmax（Phase I) [After single dose ,assessed up to 1 year]
PK parameters Cmax following single dose
- Pharmacokinetics (PK) Css,max（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters Css,max following multiple doses
- Pharmacokinetics (PK) Css,min（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters Css,min following multiple doses
- Pharmacokinetics (PK) Css,av（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters Css,av following multiple doses
- Pharmacokinetics (PK) AUCss（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters AUCss following multiple doses
- Pharmacokinetics (PK) CLss（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters CLss following multiple doses
- Pharmacokinetics (PK) Vss（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters Vss following multiple doses
- Pharmacokinetics (PK) R（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters R following multiple doses
- Pharmacokinetics (PK) DF（Phase I) [After multiple doses ,assessed up to 1 year]
PK parameters DF following multiple doses
- Pharmacokinetics (PK) Tmax（Phase I) [After single dose ,assessed up to 1 year]
PK parameters Tmax following single dose
- Pharmacokinetics (PK) AUC0-t（Phase I) [After single dose ,assessed up to 1 year]
PK parameters AUC0-t following single dose
- Pharmacokinetics (PK) AUC0-∞（Phase I) [After single dose ,assessed up to 1 year]
PK parameters AUC0-∞ following single dose
- Pharmacokinetics (PK) CL（Phase I) [After single dose ,assessed up to 1 year]
PK parameters CL following single dose
- Pharmacokinetics (PK) Vd（Phase I) [After single dose ,assessed up to 1 year]
PK parameters Vd following single dose
- Pharmacokinetics (PK) t1/2（Phase I) [After single dose ,assessed up to 1 year]
PK parameters t1/2 following single dose
- Pharmacokinetics (PK) λz（Phase I) [After single dose ,assessed up to 1 year]
PK parameters λz following single dose
- To evaluate the immunogenicity of IAP0971 in patients with advanced malignant tumors (Phase I) [After finishing Phase I, an average of 1 year]
Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAb) against IAP0971
- To evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase I) [After finishing Phase I, an average of 1 year]
Overall survival (OS) according to RECIST 1.1 or Lugano 2014
- To evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase I) [After finishing Phase I, an average of 1 year]
Objective response rate (ORR) according to RECIST 1.1 or Lugano 2014
- To evaluate the immunogenicity of IAP0971 in patients with advanced malignant tumors (Phase IIa) [After finishing Phase IIa, assessed up to 3 years]
Incidence of anti-drug antibody (ADA) and neutralizing antibodies (NAb) against IAP0971
- o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa) [After finishing Phase IIa, assessed up to 3 years]
PFS according to RECIST 1.1 or Lugano 2014
- o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa) [After finishing Phase IIa, assessed up to 3 years]
DCR according to RECIST 1.1 or Lugano 2014
- o evaluate the effectiveness of IAP0971 in patients with advanced malignant tumors (Phase IIa) [After finishing Phase IIa, assessed up to 3 years]
OS according to RECIST 1.1 or Lugano 2014
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Age 18 to 80 years, male or female. 2. Patients with histologically or cytologically confirmed advanced or unresectable solid tumors or and relapsed and/or refractory non-Hodgkin's lymphoma, who have progressed on or have been intolerant to standard treatment, or for whom no standard treatment exists.
- Dose Escalation Phase (Part A)：At least one evaluable tumor lesion per RECIST 1.1 (solid tumors) or Lugano 2014 (lymphomas).
Dose Expansion Phase (Part B)：At least one measurable tumor lesion per RECIST 1.1 (solid tumors) or Lugano 2014 (lymphomas).
-
Agree to provide previously stored tumor tissue specimens or perform biopsy to collect tumor lesion tissue and send it to the central laboratory for PD-L1 expression level detection.
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. (see Appendix 3)
-
Adequate organ function: Hematological system (No blood transfusion or hematopoietic stimulating factor therapy within 14 days) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L White blood cell count (WBC) ≥ 3.0 × 109/L Platelets (PLT) ≥ 75 × 109/L Hemoglobin (Hb) ≥ 90 g/L Hepatic function Total bilirubin (TBIL) ≤ 3 × ULN Alanine aminotransferase (ALT) ≤ 3 × ULN; Aspartate aminotransferase (AST) ≤ 3 × ULN; Renal function Creatinine clearance (Ccr) (only calculated if creatinine > 3 × ULN) ≥ 50 mL/min (calculated according to Cockcroft-Gault formula, see Appendix 7 for formula) Coagulation function Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN International normalized ratio (INR) ≤ 1.5 × ULN 7. Expected survival time of more than 3 months. 8. Eligible patients of childbearing potential (men and women) must agree to use a reliable method of contraception (hormonal or barrier method or abstinence, etc.) with their partners during the trial and for at least 90 days after study drug administration; female patients of childbearing potential (see Appendix 8 for definition) must have a negative blood or urine pregnancy test 7 days before the first administration.
-
Subjects must be informed of the study prior to the trial and voluntarily sign a written informed consent form.
Exclusion Criteria:
-
- Patients who have a severe hypersensitivity reaction to any monoclonal antibody (CTCAE 5.0 grade ≥ 3).
- Patients who received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy, and other anti-tumor treatment within 4 weeks before the first administration, except for the following: Nitrosourea or mitomycin C was received within 6 weeks before the first administration; Oral fluoropyrimidines and small molecule targeted drugs within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to the first administration.
Chinese proprietary medicines with anti-tumor indications were received within 2 weeks before the first administration.
-
Receipt of other non-marketed investigational drugs or treatments within 4 weeks before the first administration.
-
Patients who have undergone major organ surgery (excluding needle biopsy) or have significant trauma within 4 weeks before the first administration, or require elective surgery during the trial.
-
Patients who have received systemic glucocorticoids (prednisone > 10 mg/day or equivalent doses of similar drugs) or other immunosuppressive agents within 14 days before the first administration; exclude the following conditions: topical, ophthalmic, intra-articular, intranasal or inhaled corticosteroid therapy; short-term use of glucocorticoid for preventive treatment (for example, prevention of contrast agent allergy).
-
Patients who have received immunomodulatory drugs within 14 days before the first administration, including but not limited to thymosin, interleukin-2, interferon, etc.
-
Patients who have received live attenuated vaccines within 4 weeks before the first administration.
-
Previous allogeneic hematopoietic stem cell transplantation or organ transplantation.
-
The adverse reactions caused by previous anti-tumor treatment have not recovered to CTCAE 5.0 grade ≤ 1 (except for toxicity without safety risk as judged by the investigator, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.).
-
Patients with active infection who need intravenous anti-infective therapy. 11. Patients with interstitial lung disease (except for radiation pulmonary fibrosis not requiring hormone therapy).
-
History of serious cardiovascular and cerebrovascular diseases, including but not limited to: Patients with severe cardiac rhythm or conduction abnormalities, such as arrhythmia requiring clinical intervention, second-degree to third-degree atrioventricular block; QT interval (QTcF) corrected by Fridericia's method > 470 ms (see Appendix 9 for calculation formula); Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other grade 3 and above cardiovascular and cerebrovascular events within 6 months prior to the first dose; Patients with heart failure with cardiac function class ≥ II according to New York Heart Association (NYHA) (see Appendix 4) or Left Ventricular Ejection Fraction (LVEF) < 50%; Clinically uncontrolled hypertension. 13. Patients who currently have active or have had autoimmune diseases that may have recurrence (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for clinically stable autoimmune thyroid diseases, type I Diabetics.
-
Patients who have received immunotherapy and developed irAE ≥3 or immune-related myocarditis ≥2.
-
Clinically uncontrolled effusion in the third space, which is not suitable for enrollment based on the investigator's judgment.
-
Known alcohol or drug dependence. 17. Patients with mental disorders or poor compliance. 18. Women who are pregnant or breastfeeding. 19. The subject has a history of other serious systemic diseases or other reasons that make the subject unsuitable for this clinical study in the opinion of the investigator.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- SUNHO（China）BioPharmaceutical CO., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- IAP0971-I/IIa